Skip to main content
. 2021 Mar 5;34(4):721–731. doi: 10.1111/tri.13837

Figure 2.

Figure 2

Demographics and comorbidities according to occurrence of death in heart transplant recipients with COVID‐19. ACE‐I, angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blockers; CAV, cardiac allograft vasculopathy; CKD, chronic kidney disease; COVID‐19, coronavirus disease 2019; DM, diabetes mellitus; ISHLT, International Society for Heart and Lung Transplantation; M‐H, Mantel‐Haenszel. For the impact of CKD and number of background immunosuppressive therapy, data presented for Bottio et al. [52], are from the study by Iacovoni et al. [17], which were eventually included in the study of Bottio et al.